Find out how A1C and PPG values for patients on NovoLog® Mix 70/30 compared with patients on human premix insulin 70/30.1, 3
NovoLog® Mix 70/30 is an insulin analog indicated to improve glycemic control in patients with diabetes mellitus.
Additional glycemic control
Low rate of major hypoglycemia
Observational study results comparing major hypoglycemic events when switching from human premix insulin.2
Create a NovoMedLink™ ID to request samples, access educational tools, and order and share patient materials.
Have an account? Request samples.
Human premix insulin is not the only option for your patients.
Compare the differences between human and analog premix insulin, and discover the benefits of treatment with NovoLog® Mix 70/30.
aResults from patients who completed the IMPROVE™ study who were previously treated with human premix ± oral antidiabetic drug (OAD) therapy and had A1C values available at baseline and final visit. The IMPROVE™ study was a multinational, open-label, nonrandomized, 26-week, observational study that evaluated the safety and efficacy of NovoLog® Mix 70/30 in patients with type 2 diabetes; n=3856.
bNovoLog® Mix 70/30 has a flexible dosing approach that allows type 2 patients to dose within 15 minutes before or after meal initiation vs 30 minutes before meals required with human premix insulin.
Coverage and instant savings
Novo Nordisk is committed to helping make treatment more affordable for your diabetes patients
- Covered for 80% of managed care patients nationwide.
- Eligibile patients pay no more than $25 for up to two years with an instant savings card.c
More diabetes resources
NovoMedLink.com offers you access to more services, tools, and resources for all Novo Nordisk products.
- Get diabetes education materials for you, your staff, and your patients
- Access more clinical studies and professional resources
- Request different product samples